Estrogen produces both beneficial and adverse effects on cardiovascular health via mechanisms that remain unclear. Stroke-prone spontaneously hypertensive rats (SHRSP) maintained on Stroke-Prone Rodent Diet and 1% NaCl drinking water (starting at 8 weeks of age) rapidly develop stroke and malignant nephrosclerosis that can be prevented despite continued hypertension by drugs targeting angiotensin II and aldosterone actions. This study evaluated estrogen's effects in the above SHRSP model. Female SHRSP that were shamoperated (SHAM), ovariectomized (OVX) at 4 weeks of age, or OVX and treated with estradiol benzoate (E 2 , 30 µg/kg per week) were studied. In a survival protocol, OVX rats lived significantly longer (15.1 ± 0.3 weeks) compared to SHAM (13.6 ± 0.2 weeks) or OVX+E 2 rats (12.4 ± 0.2 weeks). In a protocol in which animals were matched for age, 11.5 weeks, terminal systolic blood pressure and urine protein excretion were elevated in SHAM and OVX+E 2 rats compared to OVX rats; blood urea nitrogen, renal microvascular and glomerular lesions, and plasma renin concentration were elevated in OVX+E 2 relative to SHAM or OVX rats. In a survival protocol using intact female SHRSP, treatment with an antiestrogen (tamoxifen, 7 mg/kg per week) prolonged survival by more than two weeks compared with controls (P < 0.01).
INTRODUCTION
Spontaneously hypertensive rats of the stroke-prone substrain (SHRSP) develop severe hypertension, malignant nephrosclerosis and stroke (16, 18) . Strokes in SHRSP have been reported to be pathologically similar to those in humans (33) . The renal lesions in SHRSP are characterized by thrombotic microangiopathy and are similar to those seen in patients with malignant nephrosclerosis. Female SHRSP maintained on a diet of conventional rat chow and water exhibit a diminished incidence of cerebral lesions and prolonged survival compared with male SHRSP (34, 36) . Under these conditions, the average lifespan of male SHRSP is 33 to 41 weeks (18, 33) whereas female SHRSP live beyond 50 weeks of age. However, placing SHRSP on a 1% NaCl drinking solution and Stroke-Prone Rodent Diet greatly enhances the expression of vascular damage in both male and female SHRSP. We have previously reported that under these dietary conditions, the incidence of stroke and cerebrovascular damage in female SHRSP is markedly accelerated, with mortality occurring between 12 and 15 weeks of age (10) . Although the risk of cardiovascular disease is low in premenopausal women, estrogen-containing oral contraceptives have been reported to increase the occurrence of adverse cardiovascular incidents, especially when other risk factors such as hypertension, cigarette smoking and migraine are also present (7, 8, 14) . Based on these observations, we hypothesized that estrogen plays a role in the stroke and kidney damage that occurs in saline-drinking female SHRSP. To test this hypothesis, bilateral surgical removal of the ovaries was performed in SHRSP shortly after weaning (four weeks of age) to eliminate the effects of endogenous estrogen at an early age. A low dose of estradiol benzoate (E 2 ) was then started at five weeks of age to determine whether estrogen replacement would reverse the effects of ovariectomy on the development of stroke and renal pathology. In an additional experimental series, saline-drinking female SHRSP with intact 4 ovaries were chronically treated with tamoxifen, an estrogen receptor antagonist, to determine whether this would have an effect on the development of stroke.
MATERIALS AND METHODS
Experimental animals. Experiments were performed using female SHRSP (generations F-70 to F-72) from our colony at New York Medical College. These animals were bred from National Institutes of Health stock which were derived from the SHRSP/A3N substrain described originally by Okamoto and co-workers (18) . Animals were weaned at four weeks of age and then fed a standard rodent diet (Purina Lab Chow # 5001; Ralston-Purina, St. Louis, MO) and allowed tap water ad libitum unless otherwise indicated by the experimental protocols. They were housed in a room at an ambient temperature of 22 ± 1°C with a 12-h light/12-h dark cycle. Surgical procedures. Bilateral ovariectomy was performed when the animals reached four weeks of age as described previously (6) . Rats were anesthetized with a mixture of 30% oxygen, 67% nitrous oxide and 3% isoflurane (Aerrane, Anaquest, Madison, WI) and the surgical sites were shaved and then disinfected with 70% ethanol. The abdominal cavity was entered through a 1-cm retroperitoneal incision and the ovary exposed with forceps. The site immediately rostal to the uterus was clamped with a microhemostat and the ovary was then excised. The uterus was gently placed back inside the abdominal cavity, the muscle layer sutured, and the skin incision closed with wound clips. Ovariectomy took about four minutes to 5 perform in each animal including the time for induction of and emergence from anesthesia. The rats recovered fully within 24 h of surgery.
Protocol 1 (Survival study).
Three groups were studied: ovariectomized SHRSP (OVX, n = 4), sham-operated SHRSP (SHAM, n = 6) and ovariectomized SHRSP treated with E 2 that was purchased from Sigma, St. Louis, MO (OVX + E 2 , n = 7). E 2 (30 µg/kg, s.c., divided among 3 doses each week) or an equal volume of vehicle (sesame oil, 200 µl/kg) was injected three times each week starting at 5 weeks of age. This dose of estrogen was chosen based on data from previous studies showing that this regimen effectively restores uterine weight (6, 20) and can increase circulating estrogen levels to 60 -250 pg/mL (15) in ovariectomized rats. At 8 weeks of age, all rats were given 1% NaCl solution to drink and fed Stroke-Prone Rodent Diet (#39-288, Zeigler Brothers, Inc., Gardners, PA) ad libitum. The latter diet has been reported to cause a higher incidence of stroke in SHRSP (35) and possesses a lower content of potassium (0.7 vs.
1.2% by weight) and protein (17 vs. 22% by weight) than the standard diet (27) . Treatment was continued until death which was the primary endpoint in this experimental series.
Protocol 2 (Age-matched study). Three groups were studied: ovariectomized SHRSP (OVX, n = 13), sham-operated SHRSP (SHAM, n = 14), and ovariectomized SHRSP treated with E 2 (OVX + E 2 , n = 9). Surgery was performed at 4 weeks of age and treatment with E 2 or its vehicle was started at 5 weeks of age as in Protocol 1. At 8 weeks of age, all animals were given 1% NaCl to drink and fed Stroke-Prone Rodent Diet. Body weight was measured three times each week. Systolic blood pressure (SBP) of awake rats was measured at weekly intervals by tail-cuff plethysmography. At 10 weeks of age, rats were placed in metabolic cages so that urine volume could be accurately collected over a 24-h period for the measurement of urinary protein excretion. Animals were killed by rapid decapitation at 11.5 weeks of age, before any 6 mortality had occurred, so that histological assessment of kidneys could be performed in groups that were matched for age. Following decapitation, the first 2 mL of blood was collected into a chilled tube containing disodium ethylenediaminetetraacetate for preparation of plasma. Two mL of blood was then collected into 12 x 75 mm polyethylene tubes for preparation of serum.
Blood samples were centrifuged at 3000 rpm at 4°C for 10 min and the supernatant collected and stored at -20°C for later analyses. The kidneys were then removed rapidly, cross-sectioned immediately and fixed in formalin for later histologic evaluation as described previously (28) .
Uteri, the growth of which are influenced by estrogen, were also removed at death and dissected free of fat and allowed to dry for at least 48 h before determination of dry weight.
Protocol 3 (Tamoxifen study).
In a third experimental series, 12 female SHRSP were fed Stroke-Prone Rodent Diet and given a 1% NaCl solution ad libitum to drink starting at 8 weeks of age. Animals were divided into two treatment groups: an experimental group (n = 6) that received tamoxifen as the free base (Sigma) and a control group of littermates (n = 6) that received the vehicle (sesame oil, Sigma). Treatment with tamoxifen (7 mg/kg per week s.c., divided among three alternate-day doses) or vehicle (1.0 mL/kg per week s.c. of sesame oil) was started at 7.3 weeks of age. This dose of tamoxifen is reported to produce maximal levels of estrogen antagonism (20) . SBP of awake animals was measured at weekly intervals by tail-cuff plethysmography. Body weight was measured at least three times each week. The hearts, kidneys, adrenal glands, and uteri of rats that died were removed and weighed immediately.
Uteri, trimmed of all perimetrial fat, were allowed to dry to constant weight.
Experimental procedures. SBP was measured using a Natsume KN 210 manometer and tachometer (Peninsula laboratories, Inc., Belmont, CA). Rats were warmed at 37°C for 10 min 7 and allowed to rest quietly in a Lucite chamber before tail-cuff plethysmography. Following a 5-min stabilization period, an average of nine blood pressure readings was obtained from each rat.
Analytical procedures. Plasma renin concentration (PRC) was measured, by assay of angiotensin I (Ang I) generated during incubation of a 25 µl plasma sample with 0.5 mL of plasma from 48-hour nephrectomized rats. Ang I was measured using RIA kits purchased from New England Nuclear, Boston, MA. Renin concentration was expressed as ng of Ang I generated per mL plasma per hour of incubation (ng/mL/h). Blood urea nitrogen (BUN) in serum samples was measured with a colorimetric diagnostic kit (Sigma). Urinary protein was measured by the sulfosalicyclic acid turbidity method as previously described (27) . Statistical analysis. Data for multiple observations over time were analyzed by repeated measures analysis of variance for overall treatment effects, using software package SAS (Statistical Analysis System, Cary, NC) and Newman-Keul's test for comparison of treatment groups at different times. When appropriate, data were transformed (square root) prior to analysis to normalize group variances. Some data were analyzed using unpaired t-tests.
Differences between means were considered statistically significant at P < 0.05. Cumulative % survival curves were analyzed using the BMDP software package (BMDP Statistical Software, Inc., Los Angeles, CA) for Mantel-Cox statistics. 9 
RESULTS
Survival study. Female SHRSP that were sham operated for OVX began to show signs of stroke at 12 weeks of age and died between 12.7 and 14.4 weeks of age (Fig. 1) . The average age at death in the SHAM group was 13.6 ± 0.2 weeks. OVX increased longevity of SHRSP by approximately 2 weeks (the average age at death was 15.1 ± 0.4 weeks) relative to their shamoperated littermate controls (P < 0.01). E 2 replacement reversed the effect of OVX to prolong survival and hastened mortality relative to SHAM SHRSP (P < 0.01). All animals in the OVX + E 2 group showed neurological signs of stroke and died between 12.1 to 13.4 weeks of age.
Histological analysis of the brains revealed cerebrovascular lesions as we have previously described (10) , indicating that these animals had succumbed to strokes. There was no difference in the heart, kidney and adrenal gland weight as a percentage of body weight among the groups (Table 1) . Changes in body weight and uterine weight due to OVX or E 2 treatment were consistent with prior observations (6, 20) .
Age-matched study. Female SHRSP in this protocol underwent the same experimental preparation and treatment as the animals in the survival protocol except that these animals were all sacrificed at 11.5 weeks of age, which was prior to the anticipated onset of mortality. The changes in body weight over time showed no difference among the groups until 6.5 weeks of age (Fig. 2) . Thereafter, body weight was less in the OVX + E 2 compared to OVX, and at 10 weeks of age the OVX + E 2 group was less compared to either the OVX or SHAM groups. OVX was associated with a significant increase in body weight compared with SHAM starting at 7.5 weeks of age. SBP did not differ among the groups at 9.2 weeks of age (Fig. 3) . SBP was lower in OVX compared with OVX + E 2 at 10.3 weeks of age and lower compared with either SHAM or 10 OVX at 11.5 weeks of age. SBP was slightly but significantly higher in OVX + E 2 compared with SHAM only at 10.3 weeks of age.
At 11.5 weeks of age, there was no difference in PRC or BUN between OVX compared with SHAM; however, PRC and BUN were greater in OVX + E 2 compared with either OVX or SHAM (Table 2) . One week before sacrifice, at 10.5 weeks of age, OVX + E 2 exhibited proteinuria (27.7 ± 7.9 mg/day) which was 4 times greater than in SHAM or OVX (P < 0.01). At 11.5 weeks of age, SHAM exhibited elevated urinary protein excretion compared with OVX; and OVX + E 2 exhibited significantly greater urinary protein excretion compared with OVX or SHAM ( Table 2 ). Urinary protein excretion remained at baseline levels in OVX. Table 2 . Microvascular and glomerular injury were significantly greater in SHAM than OVX and significantly greater in OVX + E 2 compared with either SHAM or OVX ( Table 2 ).
Bilateral ovariectomy was associated with a 90% decrease in uterine dry weight compared to sham-operated littermates, indicative of estrogen deficiency ( Table 2 ). E 2 replacement in OVX SHRSP increased uterine dry weight by 7-fold, compared to OVX alone.
At 11.5 weeks, absolute uterine dry weight was less in OVX + E 2 than SHAM, but E 2 -treated rats were already exhibiting notable debilitation and weight loss secondary to the microvascular pathology. When factored for body weight, the uterine to body weight ratios were nearly identical in these two groups.
Tamoxifen treatment of SHRSP with intact ovaries. Fig. 5 shows the survival of salinedrinking female SHRSP that were treated chronically with either tamoxifen or vehicle starting at 7.3 weeks of age. All animals in the vehicle-treated group showed neurological signs of stroke and died between 12.7 to 14.3 weeks of age. The average age at death was 13.2 ± 0.3 weeks in vehicle-treated SHRSP. The first tamoxifen-treated SHRSP died at 13.1 weeks of age and one tamoxifen-treated rat survived much longer than the others and was killed at 23 weeks of age (data not shown). Survival was significantly increased in the tamoxifen-treated group (P < 0.01, Mantel-Cox statistics). Histologic examination of the brains showed evidence of cerebrovascular lesions in both groups. SBP became severely elevated as a function of time with little difference 12 between the groups (Fig. 6A) . Body weight was also significantly lower in tamoxifen-treated SHRSP starting at 9.5 weeks of age (Fig. 6B) . There was no difference between the groups after 11 weeks of age as the vehicle-treated rats began to show stroke signs, became debilitated and lost body weight. Post mortem body weight (121.1 ± 7.2 vs. 115.7 ± 3.5 g) and the absolute weight of the heart (0.73 ± 0.02 vs. 0.78 ± 0.03 g), kidneys (1.33 ± 0.03 vs. 1.43 ± 0.09 g), adrenal glands (64.7 ± 4.9 vs. 60.0 ± 4.8 mg) and uterine dry weight (45.6 ± 4.3 vs. 45.4 ± 5.5 mg) did not differ between the groups. 13 
DISCUSSION
The present results indicate a role for estrogen in promoting stroke and renal microvascular injury in saline-drinking female SHRSP. In particular, survival was prolonged and renal vascular pathology was reduced by OVX, which diminishes endogenous estrogen levels, or by treatment with the antiestrogen tamoxifen. Moreover, E 2 replacement fully reversed the effect of OVX to diminish stroke-related mortality and renal vascular lesions in salinedrinking SHRSP. Other studies have shown a decrease in pathology associated with estrogen in SHRSP and in other stroke models (1, 3). However, an important difference is that both of these studies have employed middle cerebral artery occlusion to create ischemic strokes as opposed to our studies in which cerebral microvascular injury occurs spontaneously with consequent cerebrovascular hemorrhage and/or microinfarction, which is associated with malignant hypertension. We previously reported that at least 50% of female SHRSP exhibit neurological signs of stroke by 12 weeks of age when fed Stroke-Prone Rodent Diet and given 1% NaCl to drink (10) . When Enovid, an oral contraceptive preparation containing both estrogen and progestin, was administered to female SHRSP fed a similar low-protein fish diet and 1% NaCl there was an even further acceleration of lethal strokes (31) . However, Enovid did not provoke cerebrovascular damage in female SHRSP fed a regular diet, even though it exacerbated the naturally occurring high blood pressure in these rats (30) . These observations suggest that saline-drinking female SHRSP serve as a suitable experimental model for studying the adverse systemic vascular effects of estrogen.
Previous studies have reported that physiological doses (1 and 10 µg subcutaneous injections) of estradiol resulted in plasma levels at one hour of 250 pg/mL (1 µg dose) and 2000 pg/mL (10 µg dose) both of which fell to less than 60 pg/mL by six hours (15) . Since the rats in 14 our study received a comparable dose (10 µg/Kg three times per week by the same route) the plasma levels achieved should be within the range of the estrous cycle, ~30 pg/mL in metestrous to ~140 pg/mL in proestrous (3). We had previously reported that this replacement dose of E 2 provides a robust response in terms of its uterotrophic action (6, 20) . Although absolute uterine weight of OVX + E 2 (11.5 week-old) was not fully restored to the level observed in age-matched SHAM, this parameter may have been affected by debilitation related to the vascular pathology.
When factored for body weight, the values for these groups were nearly identical.
Our observations may provide a correlate to those found clinically. In premenopausal women, estrogen doses supplied in oral combination contraceptives have been associated with a slight but significant increase in the risk for stroke (8) . However, when other risk factors are present, the incidence of stroke is markedly increased by estrogen (14) . Among women who smoke cigarettes and have migraines, oral contraceptive use increased the risk for stroke by 34 fold. It is tempting to speculate that SHRSP parallel this clinical profile. These animals not only have hypertension and impaired endothelial-dependent relaxation responses (29) , as observed in patients who smoke cigarettes, but also display abnormalities in their cerebrovascular circulation as may be observed in patients with migraine. In cross-sectional studies of postmenopausal women, estrogen doses utilized for hormone replacement therapy were found to be associated with major cardiovascular protective effects (24) . The beneficial actions of estrogen were attributed to improved lipid profile, increased production of nitric oxide, decreased production of endothelin and decreased intracellular calcium in arterial smooth muscle (2) . However, estrogens are known to increase thromboembolism and the results of the prospective HERS trial indicated that among women with established coronary disease, daily use of conjugated equine estrogens and medroxyprogesterone acetate increased the risk for myocardial infarction within 15 the first year of treatment with decreased risk during years 3 to 5 (11) . The results of the HERS II study indicated that this beneficial effect did not persist during additional years of follow-up and that after 6.8 years, hormone therapy did not reduce the risk of cardiovascular events (9) . Thus, the clinical or experimental setting in which estrogen is used may be of critical importance with regard to vascular complications.
In order to better characterize the pathogenesis of the adverse vascular effects of estrogen in SHRSP, we performed a second study under identical experimental conditions, with the exception that animals were sacrificed at 11.5 weeks of age. This early age was selected as it was before any mortality was observed in the survival studies. In agreement with the protective action observed against the onset of stroke, OVX reduced the degree of proteinuria and renal vascular and glomerular damage that developed, compared with SHAM at 11.5 weeks of age.
Lower SBP in OVX may have contributed to the vascular protective effect observed in these animals; however, SBP did not differ between SHAM and OVX + E 2 and thus cannot account for the increased renal pathology in OVX + E 2 compared with SHAM. Several other studies have also implicated a role for estrogen in the production of renal injury. In the spontaneously hypercholesterolemic Imai rat, estrogen administration aggravated the development of proteinuria and glomerular injury (17) . A similar aggravating effect of estrogen has been reported in female analbuminemic rats (13) and in female obese Zucker rats (25) . In our studies, estrogen fully reversed the protective effect of OVX on proteinuria and renal damage and increased the degree of proteinuria, renal damage and elevated BUN relative to SHAM.
Although we cannot be sure why OVX + E 2 developed worse pathology relative to SHAM, one possibility is that endogenous progesterone, which was not replaced in our studies, may have had an effect to ameliorate the action of estrogen. Together, our observations in female SHRSP and 16 other animal models at risk for systemic vascular disease provide evidence for a promotive action of estrogen to enhance microvascular damage.
If endogenous estrogen levels play a role to promote vascular damage in female SHRSP, interventions that not only decrease estrogen levels (OVX) but also block the actions of estrogen at its receptor (tamoxifen), may decrease the incidence of stroke in these animals. Consistent with our findings with OVX, tamoxifen prolonged survival of saline-drinking, ovary-intact SHRSP. Unlike OVX however, tamoxifen failed to lower SBP in these animals. This may relate to the fact that tamoxifen is an estrogen receptor modulator and has been shown to antagonize estrogen effects in some target tissues but to act like estrogen in others. The effect of tamoxifen therefore may not necessarily be identical to ovariectomy. Tamoxifen has been reported to exert estrogen-like effects to suppress growth in rats and, more notably, to increase the risk of thromboembolism. Thus, the protective effect of tamoxifen in our present study suggests that the adverse effect of estrogen was not the consequence of its pro thrombotic activity. Tamoxifen has been used clinically to prevent nephropathy in patients with lupus nephritis, an autoimmune disease with acute and/or chronic inflammation believed to be aggravated by hyperestrogenemia, and to diminish nephropathy in animal models of lupus (32) . The ability of tamoxifen to reduce levels of C-reactive protein and other markers of inflammation (5) suggests that a proinflammatory effect of estrogen may be responsible for the ability of this steroid hormone to promote vascular injury in this disease.
Other mechanisms might also contribute by which estrogen may promote the development of vascular pathology in female SHRSP. Activation of the renin-angiotensinaldosterone system would be a likely possibility based on our previous studies (21, 26, 27) , which were performed in male SHRSP. Consistent with this notion, PRC was significantly 17 enhanced in OVX + E 2 and slightly reduced in OVX compared with SHAM. However, this association may have been the response to, rather than the cause of, renal vascular injury in these animals. We have also found that aldosterone is a critical mediator of the development of thrombotic microangiopathy not only in salt-loaded SHRSP (21) but also in L-NAME/Ang II/NaCl treated rats (23) . This effect of aldosterone has been associated with a vascular inflammatory phenotype (22) and may set the stage for a vicious cycle of events in which vascular injury begets inflammation, which begets vascular injury and may explain the malignant course of events leading to end-organ damage in SHRSP. We have not measured aldosterone levels in this experiment. Nonetheless, based on the high PRC in the adrenal-intact animals, we expect that aldosterone levels would also be elevated. The ability of estrogen to accelerate the progression of vascular injury under the conditions of our study may thus be due to its proinflammatory actions, either directly of via elevation in aldosterone. In postmenopausal women, hormone replacement therapy has been associated with an increase in C-reactive protein and other markers of inflammation (5) . In the rat, estrogen has been reported to have proinflammatory or antiinflammatory actions depending upon the dose, duration of exposure and the experimental conditions (4) . Another possible mechanism is that E 2 may promote thrombosis through its actions to decrease antithrombin III or to increase Factors VII and X (19) . Previous studies have also shown that estrogen treatment stimulates the formation of a tissue factor (TF)-like procoagulant in the immature rat uterus (12) . TF is thought to be involved in the local formation of thrombin, which is a potent mitogen. In addition, estrogen is known to increase plasma protein infiltration into the uterus. By analogy, an increase in vascular permeability with plasma protein influx into the vessel wall is thought to be one of the initial events in the development of microvascular lesions of thrombotic microangiopathy in SHRSP. The precise 18 mechanism by which estrogen promotes vascular injury in saline-drinking female SHRSP will require further investigation.
In conclusion, our findings demonstrate that OVX, which diminishes endogenous estrogen levels, or chronic treatment with tamoxifen, an antiestrogen, significantly prolonged survival in saline-drinking female SHRSP. OVX reduced the degree of proteinuria and renal microvascular and glomerular damage that developed compared with SHAM at 11.5 weeks of age. E 2 replacement fully reversed the effect of OVX to diminish stroke-related mortality and ameliorate renal pathology in saline-drinking SHRSP. The present results indicate a role for estrogen in promoting stroke and renal vascular injury in saline-drinking female SHRSP. starting at 7.3 weeks of age. All animals were given 1% NaCl to drink and Stroke-Prone Rodent Diet ad libitum starting at 8 weeks of age. Tamoxifen shifted the mortality curve to the right of that of the sham-operated animals as was seen with ovariectomy (see Figure 1 ). stroke-prone spontaneously hypertensive rats (SHRSP) with intact ovaries that were chronically treated with tamoxifen (7 mg/kg per week, s.c.) or vehicle (sesame oil) starting at 7.3 weeks of age. All animals were given 1% NaCl to drink and Stroke-Prone Rodent Diet ad libitum starting
